Maraviroc Waymade (Maraviroc)

Maraviroc works by selectively blocking the CCR5 co‑receptor on CD4+ T‑cells. This prevents the HIV‑1 virus from binding to the receptor and entering the cell, thereby inhibiting a key step in the viral life cycle and reducing the spread of infection.

The dosage of Maraviroc is individualized and set by a qualified prescriber based on the patient’s clinical status, viral load, and concomitant medications. Healthcare professionals determine the appropriate strength, frequency, and duration of therapy.

Safety data for Maraviroc during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare provider.

To order Maraviroc Waymade, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maraviroc belongs to the CCR5 antagonist class, differing from nucleoside reverse transcriptase inhibitors and protease inhibitors. Its unique mechanism targets viral entry rather than replication, offering an alternative for patients with resistant virus strains or those needing a regimen with a distinct side‑effect profile.

Maraviroc Waymade should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposure to extreme temperatures.

Maraviroc is administered orally, typically as a tablet taken with food to enhance absorption. The exact dosing schedule is prescribed by a healthcare professional and should be followed consistently to maintain therapeutic drug levels.

Serious risks include severe liver injury, anaphylactic reactions, QT interval prolongation, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these events, and therapy should be discontinued if they occur.

Maraviroc should not be used in patients whose HIV‑1 virus does not use the CCR5 co‑receptor, as confirmed by tropism testing. It is also contraindicated in individuals with known hypersensitivity to Maraviroc or any of its excipients.